Chemomab Therapeutics Ltd. (CMMB) Cash Flow Statement
Chemomab Therapeutics Ltd. (CMMB) generated -$8.7M of operating cash flow over the twelve months to 2026-06-30, spent $6000 on capital expenditure and had free cash flow of -$8.7M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CMMBChemomab Therapeutics Ltd.Follow CMMB — free
—
Price chart with a free account
- Market cap
- 7.5M
- P/E TTM
- 1.1
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -16.5 | -5.2 | -12.4 | -20.4 | -23.6 | -15.4 | -11.1 | -8.7 | |
| Capital expenditure | 0.1 | 0.0 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | -0.0 | |
| Free cash flow | -16.6 | -5.3 | -12.6 | -20.4 | -23.6 | -15.4 | -11.1 | -8.7 | |
| Stock-based compensation | 1.2 | 0.1 | 2.0 | 3.2 | 1.5 | 0.6 | 0.6 | — |
USD millions · SEC XBRL
Chemomab Therapeutics Ltd. — questions
- What is Chemomab Therapeutics Ltd.'s operating cash flow?
- -$8.7M over the twelve months to 2026-06-30.
- How much does Chemomab Therapeutics Ltd. spend on capital expenditure?
- $6000 over the twelve months to 2026-06-30.
- What is Chemomab Therapeutics Ltd.'s free cash flow?
- -$8.7M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Chemomab Therapeutics Ltd.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.